<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366209</url>
  </required_header>
  <id_info>
    <org_study_id>PIPF-016</org_study_id>
    <nct_id>NCT01366209</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the
      Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study
      objectives are to confirm the treatment effect of pirfenidone compared with placebo on change
      in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary
      fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo
      in patients with IPF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">555</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo equivalent given as 3 divided doses 3 times per day.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Select Inclusion Criteria:

          1. Diagnosis of idiopathic pulmonary fibrosis (IPF), consistent with the ATS 2011
             Guidelines, of 6-48 months' duration

          2. Age 40 to 80 at randomization

          3. Percent Forced Vital Capacity (%FVC) ≥50% and ≤90% at screening

          4. Percent Carbon Monoxide Diffusing Capacity (%DLCO) ≥30% and ≤90% at screening

        Select Exclusion Criteria:

          1. Forced expiratory volume in one second (FEV1)/FVC ratio &lt;0.8 after administration of
             bronchodilator at Screening

          2. Expected to receive a lung transplant within 1 year from randomization or, for
             patients at sites in the United States, on a lung transplant waiting list at
             randomization

          3. Known explanation for interstitial lung disease

          4. History of asthma or chronic obstructive pulmonary disease

          5. Active infection

          6. Ongoing IPF treatments including investigational therapy, immunosuppressants, and
             cytokine modulating agents

          7. History of unstable or deteriorating cardiac or pulmonary disease (other than IPF)
             within the previous 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>For additional information, call InterMune Medical Information Telephone: 1-888-486-6411</last_name>
    <role>Study Chair</role>
    <affiliation>InterMune</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InterMune Inc.</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <results_first_submitted>February 27, 2015</results_first_submitted>
  <results_first_submitted_qc>February 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2015</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pirfenidone</keyword>
  <keyword>ASCEND</keyword>
  <keyword>IPF</keyword>
  <keyword>FVC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Arm</title>
          <description>Pirfenidone: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Placebo: Placebo equivalent given as 3 divided doses 3 times per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243">Participants completing study assessment at Week 52 were completers, even if treatment was withdrawn</participants>
                <participants group_id="P2" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lung transplantation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsors decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Arm</title>
          <description>Pirfenidone: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Placebo: Placebo equivalent given as 3 divided doses 3 times per day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="278"/>
            <count group_id="B2" value="277"/>
            <count group_id="B3" value="555"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52</title>
        <time_frame>52 weeks</time_frame>
        <population>Intent to Treat all randomized Patient</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Pirfenidone: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Placebo equivalent given as 3 divided doses 3 times per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52</title>
          <population>Intent to Treat all randomized Patient</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decline or &gt;=10% or Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Decline (Change &gt;0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Arm</title>
          <description>Pirfenidone: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Placebo: Placebo equivalent given as 3 divided doses 3 times per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cor Pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower respiratiory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="278"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhage intercranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>IVth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous tension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="253" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="33" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="278"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="112" subjects_affected="62" subjects_at_risk="278"/>
                <counts group_id="E2" events="101" subjects_affected="60" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="61" subjects_affected="49" subjects_at_risk="278"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="278"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="278"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="138" subjects_affected="100" subjects_at_risk="278"/>
                <counts group_id="E2" events="46" subjects_affected="37" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" events="38" subjects_affected="24" subjects_at_risk="278"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="74" subjects_affected="36" subjects_at_risk="278"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="93" subjects_affected="58" subjects_at_risk="278"/>
                <counts group_id="E2" events="55" subjects_affected="48" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="38" subjects_at_risk="278"/>
                <counts group_id="E2" events="49" subjects_affected="34" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="278"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="278"/>
                <counts group_id="E2" events="40" subjects_affected="30" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="78" subjects_affected="61" subjects_at_risk="278"/>
                <counts group_id="E2" events="79" subjects_affected="56" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="278"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="278"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="278"/>
                <counts group_id="E2" events="33" subjects_affected="20" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="278"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="88" subjects_affected="49" subjects_at_risk="278"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="278"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="117" subjects_affected="72" subjects_at_risk="278"/>
                <counts group_id="E2" events="96" subjects_affected="64" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="278"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="104" subjects_affected="70" subjects_at_risk="278"/>
                <counts group_id="E2" events="97" subjects_affected="82" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="49" subjects_affected="41" subjects_at_risk="278"/>
                <counts group_id="E2" events="66" subjects_affected="49" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="278"/>
                <counts group_id="E2" events="43" subjects_affected="32" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="123" subjects_affected="78" subjects_at_risk="278"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

